TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01937117
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 840 mg as a loading dose, then 420 mg every 3 weeks, IV
Study: NCT02903537
Drug: Interferon-beta
Normalized name: Interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration interferon-beta
Study: NCT03359876
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15 mg, once daily
Study: NCT03359876
Drug: Warfarin sodium
Normalized name: Warfarin Sodium
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually adjusted dose
Study: NCT00428597
Drug: sunitinib malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * sunitinib malate oral starting dose 37.5 mg daily (continuous dosing).~* Dose may be decreased to 25 mg daily in case of adverse events.~* It may be increased to 50 mg daily if no response is seen after 8 weeks on treatment.~* Dosing to continue until unacceptable toxicity, progression of disease, death, or study termination.
Study: NCT01316237
Drug: GS-6620
Normalized name: GS-6620
DrugBank: GS-6620 (DB15222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-6620 tablet, 50 mg QD
Study: NCT01316237
Drug: GS-6620
Normalized name: GS-6620
DrugBank: GS-6620 (DB15222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-6620 tablet, 100 mg QD
Study: NCT01316237
Drug: GS-6620
Normalized name: GS-6620
DrugBank: GS-6620 (DB15222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-6620 tablet, 300 mg QD
Study: NCT01316237
Drug: GS-6620
Normalized name: GS-6620
DrugBank: GS-6620 (DB15222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-6620 tablet, 100 mg QD, Fasted
Study: NCT01316237
Drug: GS-6620
Normalized name: GS-6620
DrugBank: GS-6620 (DB15222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-6620 tablet, 300 mg QD, Fasted
Study: NCT01316237
Drug: GS-6620
Normalized name: GS-6620
DrugBank: GS-6620 (DB15222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-6620 tablet, 900 mg QD, Fasted
Study: NCT01316237
Drug: GS-6620 tablet, 450 mg BID
DrugBank: GS-6620 (DB15222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-6620 tablet, 450 mg BID
Study: NCT01316237
Drug: GS-6620 tablet
Normalized name: GS-6620
DrugBank: GS-6620 (DB15222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-6620 tablet, 900mg , BID
Study: NCT01316237
Drug: GS-6620 tablet
Normalized name: GS-6620
DrugBank: GS-6620 (DB15222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-6620 tablet, 900 mg
Study: NCT03306758
Drug: Sodium Bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Bicarbonate was given 1g tid for one month
Study: NCT01284166
Drug: dorzolamide hydrochloride 2.0%/brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 drop of Triple Combination Therapy (dorzolamide hydrochloride 2.0%/brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution) administered to each eye, twice daily for 12 weeks.
Study: NCT00685334
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will take olanzapine daily for 12 weeks.
Study: NCT00685334
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will take aripiprazole daily for 12 weeks.
Study: NCT00803816
Drug: everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: everolimus 1.0 - 2.5mg oral daily dosage
Study: NCT03898908
Drug: encorafenib
Normalized name: encorafenib
DrugBank: Encorafenib (DB11718)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Encorafenib 75mg and 50mg (capsules) for a 450mg daily for oral administration during 56 days and after local radiation treatment.~If no progression of disease progression (PD) is reported, treatment will continue until PD, unacceptable toxicity or death.
Study: NCT03898908
Drug: binimetinib
Normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Binimetinib 15mg (tablets) for a 45mg/12 hours for oral administration during 56 days and after local radiation treatment.
Study: NCT02654730
Drug: Dihydroartemisinin-piperaquine (DHAP) administered to G6PD deficient
Normalized name: methyl-dihydroartemisinine
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days
Study: NCT03607331
Drug: Citalopram
Normalized name: Citalopram
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citalopram is an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) class.It has U.S. Food and Drug Administration approval to treat major depression.
Study: NCT00330473
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patient specific dose, oral or injectable, before meals and/or as needed, 9 months. ( patients and investigator determine standard option therapy)
Study: NCT05156541
Drug: Interferon gamma human recombinant (IFN-G)
Normalized name: interferon gamma, porcine recombinant
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
Study: NCT04342936
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A humanized monoclonal immunoglobulin
Study: NCT01441349
Drug: IP chemotherapy
Normalized name: IP-2018
DrugBank: IP-2018 (DB19049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan/cisplatin (IP) chemotherapy~* Cisplatin(30 mg/m2) diluted into 150 ml of 0.9% NS for IV over 30 min on day 1 \&8.~* Irinotecan(65mg/m2) diluted into 200ml of 5DW IV over 90 min on day 1 \& 8~* Every 21 days
Study: NCT00452218
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg daily and dose escalated to a maximum of 400 mg twice daily
Study: NCT01717313
Drug: Omarigliptin
Normalized name: Omarigliptin
DrugBank: Omarigliptin (DB11992)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Omarigliptin 25 mg capsule administered orally once a week.
Study: NCT01717313
Drug: Placebo to Omarigliptin
DrugBank: Omarigliptin (DB11992)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Placebo to omarigliptin capsule administered orally once a week
Study: NCT01717313
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: If necessary, participants may have glycemic rescue therapy initiated with open-label metformin during Phase A of the study. Participants in the placebo treatment group who were not rescued with open-label metformin during Phase A will receive blinded metformin (starting at 500 mg orally twice daily with up-titration to 1000 mg orally twice daily) in Phase B. Participants in the omarigliptin treatment group who were rescued with open-label metformin in Phase A will continue open-label metformin during Phase B of the study.
Study: NCT01717313
Drug: Placebo to metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: During Phase B of the study, participants in the omarigliptin treatment group who did not initiate glycemic rescue therapy during Phase A will receive placebo to metformin for 30 weeks (Phase B of the study).
Study: NCT01717313
Drug: Glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If necessary during Phase B of the study, participants will initiate open-label glimepiride as glycemic rescue therapy
Study: NCT00209690
Drug: Taxotere
Normalized name: Taxotere
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: X mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT00209690
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 mg/m2, CIV (conti.in the vein) on day 1\~4 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT00209690
Drug: Briplatin
Normalized name: Aroplatin
DrugBank: Aroplatin (DB17319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/m2, IV (in the vein) on day 1\~4 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT03633721
Drug: Cannabis
Normalized name: Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7% delta9-THC cigarettes will be smoked by 'light the cigarette' (30 sec), 'get ready' (5 sec), 'inhale' (5 sec), 'hold smoke in lungs' (10 sec) and 'exhale.' Participants will smoke 3 puffs in this manner, with a 40-sec interval between each puff.
Study: NCT00375284
Drug: Pramipexole
Normalized name: Pramipexole
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02654730
Drug: Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD deficient
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.25mg/kg of primaquine on the first day of DHAP treatment.
Study: NCT02864472
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab
Study: NCT02864472
Drug: ranibizumab PRN
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ranibizumab PRN
Study: NCT04033419
Drug: Memantine
Normalized name: Memantine
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: memantine dose~* Week 1: 5 mg dose once daily~* Week 2: 5 mg dose twice daily~* Week 3: 5 mg each morning/10 mg each evening~* Week 4 through the end of Chemotherapy: 10 mg dose twice daily~* Total duration: 12 - 26 weeks (depending on chemotherapy regimen)
Study: NCT00276536
Drug: IFN
Normalized name: IFNτ
DrugBank: Interferon tau (DB16972)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN daily
Study: NCT02662647
Drug: Decitabine 20 mg/m²/day for 5 days
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01002079
Drug: BMS-708163
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsule, Oral, 125 mg, Once daily, 1 day
Study: NCT01002079
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, Oral, 600 mg, Once daily, 7 days
Study: NCT01002079
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, Oral, 600 mg, Once daily, 6 days
Study: NCT00347828
Drug: Moxifloxacin ophthalmic solution 0.5%
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00347828
Drug: Gatifloxacin ophthalmic solution 0.3%
DrugBank: Gatifloxacin (DB01044)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02026063
Drug: Telotristat etiprate
Normalized name: Telotristat etiprate
DrugBank: Telotristat (DB14218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telotristat etiprate tablet (250 mg)
Study: NCT00434135
Drug: gemcitabine plus pemetrexed, paclitaxel plus gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: gemcitabine 1,250 mg/sqm days 1\&8 + pemetrexed 500 mg/sqm day 8 paclitaxel 120 mg/sqm + gemcitabine 1,000 mg/sqm days 1\&8
Study: NCT03116945
Drug: 68Gallium Citrate
Normalized name: gallium 67 citrate
DrugBank: Gallium nitrate (DB05260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Procedure: PET/CT Imaging
Study: NCT00639938
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg Nevirapine tablet
Study: NCT00639938
Drug: HIV immune globulin solution
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% intravenous HIV immune globulin solution
Study: NCT02183519
Drug: Capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For reflex cough testing, all participants will receive various concentrations of nebulized capsaicin. Delivery of multiple concentrations and doses of capsaicin allows for accurate assessment of both the strength (airflow measures) of reflex, as well as cough sensitivity.
Study: NCT04291755
Drug: Pembrolizumab Injection
Normalized name: pembrolizumab Injection
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Any checkpoint inhibitor is acceptable
Study: NCT00982904
Drug: Fexinidazole/Placebo
DrugBank: Fexinidazole (DB12265)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00320307
Drug: abacavir
Normalized name: Abacavir
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02654730
Drug: Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg/kg primaquine administered to G6PD deficient
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.4mg/kg of primaquine on the first day of DHAP treatment.
Study: NCT02654730
Drug: Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD normal
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: G6PD normal participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.25mg/kg of primaquine on the first day of DHAP treatment.
Study: NCT02654730
Drug: Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg/kg primaquine administered to G6PD normal
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: G6PD normal participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.4mg/kg of primaquine on the first day of DHAP treatment.
Study: NCT01987128
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00212147
Drug: General anesthesia with nitrous oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00252161
Drug: Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy
Normalized name: Ts-1 (TN)
DrugBank: Gimeracil (DB09257)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy
Study: NCT01698554
Drug: bimatoprost formulation A solution
Normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
Study: NCT01698554
Drug: bimatoprost solution 0.03 %
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bimatoprost solution 0.03 % (LATISSE®) applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
Study: NCT01698554
Drug: vehicle of bimatoprost formulation A solution
Normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Vehicle of bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
Study: NCT01698554
Drug: vehicle of bimatoprost solution 0.03 %
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Vehicle of bimatoprost solution 0.03 % applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
Study: NCT00212147
Drug: General anesthesia without nitrous oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00189553
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 5 every 3/4 weeks during 6 cycles or until progression
Study: NCT00189553
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 175 mg/m² at day 1 every 3 weeks during 6 cycles or until progression
Study: NCT02282683
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone (10 to 20 mg/day, orally) combined with maximum tolerated guideline-directed medical therapy for at least 12 months
Study: NCT00744900
Drug: Pemetrexed, cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alimta 500mg/m² IV 10 min infusion and Cisplatin 75mg/m² IV 60 min on day 1. Cycle will be repeated each 21 days.Folic acid orally 400µg should begin 5-7days prior to the first dose of pemetrexed and continuing daily until 3 weeks after the last dose of pemetrexed. Vitamin B12 will be administered as a 1000 mg intramuscular injection, approximately one week before Day 1 of cycle 1 and should repeat approximately every 9 weeks Dexamethasone, 4 mg or equivalent, should be taken orally twice per day on the day before, the day of, and the day after each dose of pemetrexed.WBRT will be administered with high energy photons systematically after cycle 6 or in case of stable disease (SD) after cycle 4 or progressive disease (PD) at any time. The dose will be 3Gy by fraction, 1 fraction per day, for 10 days.
Study: NCT00200382
Drug: PS-341 (Velcade-drug)
Normalized name: PS
DrugBank: Phosphatidyl serine (DB00144)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02715687
Drug: Amiodarone
Normalized name: Amiodarone
DrugBank: Amiodarone (DB01118)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Will receive 30 days treatment with oral amniodarone of 200mg
Study: NCT01627717
Drug: Maraviroc (5 days)
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive maraviroc 150 mg tablets (1 tablet) every 12 hours from days 1 to 5 inclusively.
Study: NCT01627717
Drug: Maraviroc and boceprevir (14 days)
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: From days 6 to 19, inclusively, boceprevir 800 mg (4 capsules of 200 mg) every 8 hours with food will be given with maraviroc 150 mg (1 tablet of 150 mg) every 12 hours.
Study: NCT00410488
Drug: Palonosetron - Single Dose
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.25 mg by vein for 1 dose (day 0).
Study: NCT00410488
Drug: Palonosetron - Triple Dose
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.25 mg by vein for 3 doses (days 0, 2, 4).
Study: NCT01943565
Drug: Hydromorphone 25mcg
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal Hydromorphone 25mcg
Study: NCT01943565
Drug: Hydromorphone 50mcg
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal Hydromorphone 50mcg
Study: NCT01943565
Drug: Hydromorphone 100mcg
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal Hydromorphone 100mcg
Study: NCT03192397
Drug: Fludarabine Phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03192397
Drug: Melphalan Hydrochloride
Normalized name: melphalan hydrochloride
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03192397
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03192397
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV and PO
Study: NCT01583374
Drug: Apremilast tablet 20 mg
Normalized name: apremilast Oral Tablet
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Apremilast 20 mg was taken orally twice a day (BID)
Study: NCT00009945
Drug: clodronate
Normalized name: Clodronate
DrugBank: Clodronic acid (DB00720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600 mg PO daily
Study: NCT01583374
Drug: Apremilast tablet 30 mg BID
Normalized name: apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Apremilast 30 mg was taken orally twice a day
Study: NCT02994147
Drug: AC-201CR
Normalized name: Ac
DrugBank: Actinium (DB12860)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational product is formulated as controlled-release (CR) tablets
Study: NCT01459380
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01459380
Drug: Veliparib
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00410488
Drug: Adriamycin
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2 as an IV bolus OR 75 mg/m2 as continuous IV infusion over 72 hours (without zinecard) on Day 0.
Study: NCT00410488
Drug: Ifosfamide chemotherapy (AI)
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ifosfamide: 2.5 g/m2 IV bolus over 3 hours; days 0, 1, 2, 3 (total dose = 10 g/m2). Cycle is 3 weeks, up to 6 cycles.
Study: NCT02711280
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02711280
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00410488
Drug: Zinecard
Normalized name: Zinecard
DrugBank: Dexrazoxane (DB00380)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 750 mg/m2 as an IV bolus.
Study: NCT00410488
Drug: Mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg/m2 given simultaneously with ifosfamide day 0; then 1500 mg/m2 over 24 hour for days 0, 1, 2, and 3 (infusion completing on day 4).
Study: NCT00130897
Drug: Sutent
Normalized name: Sutent
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sutent, 25, 37.5. or 50 mg daily
Study: NCT02606032
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: active comparator